Qureator
Private Company
Total funding raised: $2.5M
Overview
Qureator is a private, pre-revenue biotech company pioneering a novel drug discovery platform that integrates advanced human-relevant disease models with artificial intelligence. The company's core technology consists of CurioChips, a high-throughput microphysiological system (MPS) that recreates complex human biology, and QuriCore AI, a multimodal neural network for predictive data analysis. This integrated approach is designed to identify new drug targets, synergistic combinations, and predict clinical outcomes, with a current focus on metastatic cancer and immunotherapy. A significant milestone includes an FDA IND approval based on its human-relevant data, signaling validation of its platform's potential to reduce reliance on animal models.
Technology Platform
Integrated platform combining CurioChips (high-throughput 3D organ-on-a-chip microphysiological systems) with QuriCore AI (a multimodal neural network for predictive data analysis). The system uses patient-derived cells to create complex human disease models for testing therapeutics, with AI used for target ID, combination discovery, and outcome prediction.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Qureator competes in the converging fields of microphysiological systems (MPS) and AI-driven drug discovery. Key competitors include public tools companies like Emulate and CN Bio in organ-on-a-chip, as well as AI biotechs like Recursion, Exscientia, and Insilico Medicine. Its differentiation lies in the tight, proprietary integration of its high-throughput CurioChip models with its QuriCore AI analytics engine.